[This Week's IPO] April Fourth Week Demand Forecast and Subscription Schedule

In the fourth week of this month (April), Curatis and Truen will conduct demand forecasting targeting institutional investors. S-Biomedics is preparing for a general subscription.

◆Curatis= Established in 2016, Curatis is a company specializing in the development of immune-related vaccines and operates both CMO (Contract Manufacturing Organization) and CDMO (Contract Development and Manufacturing Organization) businesses. The company's main technological products currently include the adult and adolescent tuberculosis vaccine QTP101 and the next-generation mRNA (messenger ribonucleic acid) COVID-19 vaccine QTP104.

The total number of shares offered is 3.5 million, with a desired public offering price per share ranging from 6,500 to 8,000 KRW. The company plans to raise approximately 28 billion KRW (based on the upper limit of the desired price band) through this offering. Demand forecasting for institutional investors will be conducted from the 25th to the 26th to finalize the offering price, followed by a general subscription from May 2nd to 3rd. The company aims to be listed in May, with Daishin Securities and Shin Young Securities serving as joint lead managers.

◆Truen= Founded in 2005, Truen primarily operates in providing AI-based video surveillance and smart home IoT (Internet of Things) solutions. In its early days, the company experienced rapid growth through the development of video servers and the release of IP cameras equipped with various video analysis functions. Since then, it has established itself as a market-leading company by building product lines related to Edge AI and AIoT.

The total number of shares offered is 2.5 million, all newly issued shares. The desired public offering price per share ranges from 10,000 to 12,000 KRW, with an expected offering amount between 25 billion and 30 billion KRW. Demand forecasting will be conducted on the 27th and 28th to finalize the offering price, followed by a general subscription on May 8th and 9th. The listing is scheduled for May, with Mirae Asset Securities as the lead underwriter.

◆S-Biomedics= The public offering price was finalized at the top of the desired band, 18,000 KRW per share. During the demand forecasting conducted on the 17th and 18th, a total of 1,246 institutions participated, resulting in a competition rate of 854 to 1. After the general subscription on the 24th and 25th, the company plans to enter the KOSDAQ market on the 4th of next month. Mirae Asset Securities is the lead underwriter.

S-Biomedics is a regenerative medicine company based on cell therapy. It possesses two core platform technologies (FECS™, TED) and eight pipelines, and has filed a total of 132 patents in major bio markets including Korea, the United States, Europe, and Japan. Among these, 87 patents have been registered, and the company continues to file supplementary patents.